Search

Your search keyword '"Dangond, Fernando"' showing total 12 results
Start Over Author "Dangond, Fernando" Topic 3. good health
12 results on '"Dangond, Fernando"'

1. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1

Author

Traboulsee, Anthony, Li, David K B, Cascione, Mark, Fang, Juanzhi, Dangond, Fernando, and Miller, Aaron

Subjects
10. No inequality, 3. Good health
Abstract

Background: In the PRISMS study, interferon beta-1a subcutaneously (IFN β-1a SC) reduced clinical and radiological disease burden at 2 years in patients with relapsing–remitting multiple sclerosis. The study aimed to characterize efficacy of IFN β-1a SC 44 μg and 22 μg three times weekly (tiw) at Year 1. Methods: Exploratory endpoints included annualized relapse rate (ARR), 3-month confirmed disability progression (1-point Expanded Disability Status Scale increase if baseline was

3. Additional file 1: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Author

Traboulsee, Anthony, Li, David, Cascione, Mark, Juanzhi Fang, Dangond, Fernando, and Miller, Aaron

Subjects
3. Good health
Abstract

Figure S1. Proportion with EDSS progression at each year by ≥2 versus 0–1 active T2 lesions at 6 months. (a) Placebo/delayed treatment group; (b) IFN β-1a 22 μg SC tiw group; (c) IFN β-1a 44 μg SC tiw group. (PDF 258 kb)

4. Additional file 7: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Author

Traboulsee, Anthony, Li, David, Cascione, Mark, Juanzhi Fang, Dangond, Fernando, and Miller, Aaron

Subjects
3. Good health
Abstract

Figure S6. Proportion relapsed at each year by ≥2 versus 0–1 active T2 lesions at 12 months. (a) Placebo/delayed treatment group; (b) IFN β-1a 22 μg SC tiw group; (c) IFN β-1a 44 μg SC tiw group. (PDF 273 kb)

5. Additional file 1: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Author

Traboulsee, Anthony, Li, David, Cascione, Mark, Juanzhi Fang, Dangond, Fernando, and Miller, Aaron

Subjects
3. Good health
Abstract

Figure S1. Proportion with EDSS progression at each year by ≥2 versus 0–1 active T2 lesions at 6 months. (a) Placebo/delayed treatment group; (b) IFN β-1a 22 μg SC tiw group; (c) IFN β-1a 44 μg SC tiw group. (PDF 258 kb)

6. Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Author

Traboulsee, Anthony, Li, David K B, Cascione, Mark, Fang, Juanzhi, Dangond, Fernando, and Miller, Aaron

Subjects
10. No inequality, 3. Good health
Abstract

Background: On-treatment magnetic resonance imaging lesions may predict long-term clinical outcomes in patients receiving interferon β-1a. This study aimed to assess the effect of active T2 and T1 gadolinium-enhancing (Gd+) lesions on relapses and 3-month confirmed Expanded Disability Status Scale (EDSS) progression in the PRISMS clinical trial. Methods: Exploratory analyses assessed whether active T2 and T1 Gd + lesions at Month 6, or active T2 lesions at Month 12, predicted clinical outcomes over 4 years in PRISMS. Results: Mean active T2 lesion number at Month 6 was significantly lower with interferon beta-1a given subcutaneously (IFN β-1a SC) 44 μg and 22 μg 3×/week (tiw) than with placebo (p

8. Additional file 7: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Author

Traboulsee, Anthony, Li, David, Cascione, Mark, Juanzhi Fang, Dangond, Fernando, and Miller, Aaron

Subjects
3. Good health
Abstract

Figure S6. Proportion relapsed at each year by ≥2 versus 0–1 active T2 lesions at 12 months. (a) Placebo/delayed treatment group; (b) IFN β-1a 22 μg SC tiw group; (c) IFN β-1a 44 μg SC tiw group. (PDF 273 kb)

9. Additional file 5: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Author

Traboulsee, Anthony, Li, David, Cascione, Mark, Juanzhi Fang, Dangond, Fernando, and Miller, Aaron

Subjects
3. Good health
Abstract

Figure S4. Proportion relapsed at each year by ≥2 versus 0–1 active T2 lesions at 6 months. (a) Placebo/delayed treatment group; (b) IFN β-1a 22 μg SC tiw group; (c) IFN β-1a 44 μg SC tiw group. (PDF 269 kb)

10. Additional file 4: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Author

Traboulsee, Anthony, Li, David, Cascione, Mark, Juanzhi Fang, Dangond, Fernando, and Miller, Aaron

Subjects
3. Good health
Abstract

Figure S3. Time to sustained EDSS progression by ≥2 versus 0–1 active T2 lesions at 6 months. (a) Placebo/delayed treatment group; (b) IFN β-1a 22 μg SC tiw group; (c) IFN β-1a 44 μg SC tiw group. (PDF 229 kb)

11. Additional file 5: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Author

Traboulsee, Anthony, Li, David, Cascione, Mark, Juanzhi Fang, Dangond, Fernando, and Miller, Aaron

Subjects
3. Good health
Abstract

Figure S4. Proportion relapsed at each year by ≥2 versus 0–1 active T2 lesions at 6 months. (a) Placebo/delayed treatment group; (b) IFN β-1a 22 μg SC tiw group; (c) IFN β-1a 44 μg SC tiw group. (PDF 269 kb)

12. Additional file 4: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Author

Traboulsee, Anthony, Li, David, Cascione, Mark, Juanzhi Fang, Dangond, Fernando, and Miller, Aaron

Subjects
3. Good health
Abstract

Figure S3. Time to sustained EDSS progression by ≥2 versus 0–1 active T2 lesions at 6 months. (a) Placebo/delayed treatment group; (b) IFN β-1a 22 μg SC tiw group; (c) IFN β-1a 44 μg SC tiw group. (PDF 229 kb)

Catalog

Books, media, physical & digital resources
See catalog results